Tudoroiu-Cornoiu, M.-R.; Șerban, R.M.; Cocioabă, D.; Niculae, D.A.; Drăgănescu, D.; Leonte, R.; Ion, A.C.; Niculae, D.
89Zr-Radiolabelling of p-NCS-Bz-DFO-Anti-HER2 Affibody Immunoconjugate: Characterization and Assessment of In Vitro Potential in HER2-Positive Breast Cancer Imaging. Pharmaceutics 2025, 17, 739.
https://doi.org/10.3390/pharmaceutics17060739
AMA Style
Tudoroiu-Cornoiu M-R, Șerban RM, Cocioabă D, Niculae DA, Drăgănescu D, Leonte R, Ion AC, Niculae D.
89Zr-Radiolabelling of p-NCS-Bz-DFO-Anti-HER2 Affibody Immunoconjugate: Characterization and Assessment of In Vitro Potential in HER2-Positive Breast Cancer Imaging. Pharmaceutics. 2025; 17(6):739.
https://doi.org/10.3390/pharmaceutics17060739
Chicago/Turabian Style
Tudoroiu-Cornoiu, Maria-Roxana, Radu Marian Șerban, Diana Cocioabă, Dragoș Andrei Niculae, Doina Drăgănescu, Radu Leonte, Alina Catrinel Ion, and Dana Niculae.
2025. "89Zr-Radiolabelling of p-NCS-Bz-DFO-Anti-HER2 Affibody Immunoconjugate: Characterization and Assessment of In Vitro Potential in HER2-Positive Breast Cancer Imaging" Pharmaceutics 17, no. 6: 739.
https://doi.org/10.3390/pharmaceutics17060739
APA Style
Tudoroiu-Cornoiu, M.-R., Șerban, R. M., Cocioabă, D., Niculae, D. A., Drăgănescu, D., Leonte, R., Ion, A. C., & Niculae, D.
(2025). 89Zr-Radiolabelling of p-NCS-Bz-DFO-Anti-HER2 Affibody Immunoconjugate: Characterization and Assessment of In Vitro Potential in HER2-Positive Breast Cancer Imaging. Pharmaceutics, 17(6), 739.
https://doi.org/10.3390/pharmaceutics17060739
